Cohort 1 | ||||
NC (n = 8) | PMC (n = 16) | PPA (n = 13) | bvFTD (n = 16) | |
Age, median years (range)a | 52 (24–65) | 53 (31–71) | 65 (52–79) | 61 (40–78) |
Female, N (%) | 4 (50) | 10 (62) | 8 (57) | 6 (37) |
Age at onset, median years (range) | – | – | 63 (50–78) | 59 (39–77) |
Years to expected onsetb, median years (range) | – | 8 (−24,+ 3) | – | – |
Mutation, N (%) | ||||
C9orf72 | – | 8 (50) | 0 | 2 (13) |
GRN | – | 8 (50) | 1 (8) | – |
VCP | – | – | – | 1 (6) |
Cohort 2 | Control (n = 18) | FTDc (n = 13) | AD (n = 79) | |
Age, median years (range)d | 81 (74–86) | 68 (50–83) | 72 (54–88) | |
Female, N (%) | 10 (56) | 4 (31) | 49 (62) |